The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery – a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.
The research team, which includes scientists from Oklahoma, Denmark, Australia and Canada, set out to find a better way to prevent blood clots without increasing the risk of bleeding. Blood clots, known as deep-vein thrombosis (DVT), affect the large veins in the lower leg and thigh. If the clot breaks free and moves through the bloodstream, it can lodge in the lungs, a condition known as pulmonary embolism (PE), which is often fatal. Pulmonary embolism is the most common preventable cause of sudden death after surgery.
Current preventive treatments include uncomfortable injections and one oral anti-clotting medicine that is difficult for patients and physicians to manage. Researchers wanted to find something better.
In a double-blind study of more than 3,000 patients, researchers tested a new type of anti-clotting drug called Apixaban, which is an oral medication. The medicine proved just as effective at preventing blood clots and reduced the risk of bleeding by half. Most importantly for patient convenience, it was much easier to use.
“This is a major step in our fight to prevent DVT and the many unnecessary deaths each year caused by blood clots after joint replacement surgery. We now have a better treatment that reduces the risk of bleeding, and a patient no longer has to endure injections by needle,” said Gary Raskob, Ph.D., a lead researcher on the project and dean of the OU College of Public Health.
Raskob, who is a renowned expert in the field, said as our population ages, the number of hip and knee replacements will skyrocket in the coming years, so an easier to use and safe preventive medicine is essential. According to the American Academy of Orthopaedic Surgeons, more than 700,000 primary total hip and knee replacements are performed each year in the United States, and that number is expected to grow to more than 3.5 million by 2030.
On average, 1 percent to 3 percent of people undergoing total joint replacement will end up with a symptomatic deep-vein thrombosis (blood clot in the legs) or a pulmonary embolism (a blood clot in the lungs).
Apixaban is now being studied in Phase III clinical trials and, if approved by the U.S. Food and Drug Administration, will be an important option for patients having joint replacement surgery.
Diane Clay | EurekAlert!
The FiTS app now offering cooking videos as it expands its concept for long-term behavior modification
18.09.2018 | vitaliberty GmbH
The microbiota in the intestines fuels tumour growth
18.09.2018 | Technische Universität München
Thin-film solar cells made of crystalline silicon are inexpensive and achieve efficiencies of a good 14 percent. However, they could do even better if their shiny surfaces reflected less light. A team led by Prof. Christiane Becker from the Helmholtz-Zentrum Berlin (HZB) has now patented a sophisticated new solution to this problem.
"It is not enough simply to bring more light into the cell," says Christiane Becker. Such surface structures can even ultimately reduce the efficiency by...
A study in the journal Bulletin of Marine Science describes a new, blood-red species of octocoral found in Panama. The species in the genus Thesea was discovered in the threatened low-light reef environment on Hannibal Bank, 60 kilometers off mainland Pacific Panama, by researchers at the Smithsonian Tropical Research Institute in Panama (STRI) and the Centro de Investigación en Ciencias del Mar y Limnología (CIMAR) at the University of Costa Rica.
Scientists established the new species, Thesea dalioi, by comparing its physical traits, such as branch thickness and the bright red colony color, with the...
Scientists have succeeded in observing the first long-distance transfer of information in a magnetic group of materials known as antiferromagnets.
An international team of researchers has mapped Nemo's genome, providing the research community with an invaluable resource to decode the response of fish to...
Graphene is considered a promising candidate for the nanoelectronics of the future. In theory, it should allow clock rates up to a thousand times faster than today’s silicon-based electronics. Scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) and the University of Duisburg-Essen (UDE), in cooperation with the Max Planck Institute for Polymer Research (MPI-P), have now shown for the first time that graphene can actually convert electronic signals with frequencies in the gigahertz range – which correspond to today’s clock rates – extremely efficiently into signals with several times higher frequency. The researchers present their results in the scientific journal “Nature”.
Graphene – an ultrathin material consisting of a single layer of interlinked carbon atoms – is considered a promising candidate for the nanoelectronics of the...
03.09.2018 | Event News
27.08.2018 | Event News
17.08.2018 | Event News
18.09.2018 | Materials Sciences
18.09.2018 | Materials Sciences
18.09.2018 | Information Technology